Eliquis to face generic competition in late 2026?
Eliquis to face generic competition in late 2026? Bristol Myers Squibb (BMS) and Pfizer’s oral blood thinner – Eliquis® (Apixaban) was approved in the United
Eliquis to face generic competition in late 2026? Bristol Myers Squibb (BMS) and Pfizer’s oral blood thinner – Eliquis® (Apixaban) was approved in the United
U.S. FDA approval of BioLineRx’s APHEXDA™ (Motixafortide) in combination with Filgrastim (G-CSF) – a ray of hope for patients with Multiple Myeloma BioLineRx Ltd., a
Tysabri® Biosim approved under REMS program In June 2023, the US district court’s rejection in Biogen vs Sandoz’s Tysabri®’s patent infringement case where Biogen alleged
Stelara® Biosimilars: Relief for plaque psoriasis patients Johnson & Johnson’s (J&J) plaque psoriasis blockbuster drug, Stelara® (Ustekinumab), gained its first approval from U.S. FDA in September 2009.
Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.
Copyright 2023 All right reserved by WSLI. Designed by Webpeckers.